RxDoctor Payments Data

Arthur Sit, MD

Ophthalmology · Rochester, MNNPI 1295713170

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $25,250 of the $32,998 with a category attached, or 76.5%. AbbVie accounts for 82.4% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $30,075 and has fallen 99.9% since, to $31 in 2025. Among ophthalmology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$32,998in general payments, 2019–2025

Across 34 payments — averaging $970.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$27K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$6K
  • Alcon$173
  • Aerie Pharmaceuticals, Inc.$83
$6,500in research payments, 2019–2025

Across 1 payment — averaging $6500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$7K

What the payments were for

  • Consulting fees$25,25077%
  • Grants$5,00015%
  • Travel & lodging$1,4654%
  • Food & beverage$1,2834%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,998 in reported general payments places this provider in the 95th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota

Medicare billing

Part B allowed, 2024
$174,680
Medicare patients
296
Services billed
1,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate53$17,570
Prednisolone Acetate161$7,861
Brimonidine Tartrate71$2,655
MoxifloxacinMoxifloxacin Hcl101$1,686
Ketorolac Tromethamine66$1,620
Latanoprost137$1,520
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat56$920
Timolol Maleate65$460

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa$83$17,57053 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 330 ophthalmology providers in Minnesota.

Other ophthalmology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →